SER — Serina Therapeutics Share News
0.000.00%
Last trade - 00:00- $41.91m
- $21.97m
- $0.13m
Brief: Serina Therapeutics - Offers Up To 12,500,000 Shares Of Common Stock By Roth Principal Investments - SEC Filing
Serina Therapeutics Q2 net loss widens on higher expenses
Brief: Serina Therapeutics Appoints Farrell Simon To Its Board Of Directors
Brief: Serina Therapeutics Completes Sentinel Dosing In Cohort 1 Of Phase 1B Registrational Trial Of SER-252
Brief: Serina Therapeutics Announces NYSE American Acceptance Of Continued Listing Compliance Plan
Serina Therapeutics' 2025 net loss widens as R&D expenses jump
Chairman Of Board - SEC Filing
Brief: Serina Therapeutics Announces FDA Clearance Of Ind Application For Ser-252 For The Treatment Of Advanced Parkinson’S Disease
Brief: Serina Therapeutics Says US FDA Places Clinical Hold On SER-252 Program
Brief: Serina Therapeutics Says Submits IND To FDA, Receives HREC Approval In Australia For SER-252- SEC Filing
Brief: Serina Therapeutics Says May Offer And Sell Shares Of Common Stock Of Up To $13.3 Million
Brief: Serina Therapeutics Secures $5 Million Funding
Brief: Serina Therapeutics Files For Mixed Shelf Of Upto $100 Million - SEC Filing
U.S. RESEARCH ROUNDUP-Beam Therapeutics, Lennar, Redfin
Brief: Serina Therapeutics Appoints Dr. Jay Venkatesan To Its Board Of Directors
Brief: Serina Therapeutics Receives Second $5 Mln Tranche To Strengthen Cash Position
Brief: Serina Therapeutics Announces Sale Of Univerxome Subsidiary
Brief: Serina Therapeutics Welcomes Karen J. Wilson To Its Board Of Directors
Brief: Serina Therapeutics- On Sept 8, Board Appointed Steven Ledger To Be Chief Executive Officer